SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Taysha Gene Therapies Q3 net loss widens on higher R&D costs

Taysha Gene Therapies Q3 net loss widens on higher R&D costs Overview US gene therapy developer's Q3

GPCRPEPGTSHATYRA

Related stories